Associated tags: Clinical trial, Research, Patient, GI, Medicine, Biotechnology, University, Drug development, IBD
Locations: MASH, ONTARIO, PIERRE, LONDON, EUROPE, ASIA, CANADA, UNITED STATES, LATIN AMERICA
LONDON, ON, Jan. 8, 2024 /PRNewswire/ - Alimentiv Inc. ("Alimentiv") is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024.
Key Points:
- LONDON, ON, Jan. 8, 2024 /PRNewswire/ - Alimentiv Inc. ("Alimentiv") is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024.
- Pierre brings a wealth of experience, with over 25 years of executive expertise managing businesses in Canada, Europe, and Asia.
- His experience, coupled with a commitment to a people-first approach, aligns with the culture and values that are integral to Alimentiv.
- I look forward to what we can accomplish together", said Pierre Gaudreault, incoming CEO for Alimentiv.
LONDON, ON, Jan. 8, 2024 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv") is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024.
Key Points:
- LONDON, ON, Jan. 8, 2024 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv") is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024.
- Pierre brings a wealth of experience, with over 25 years of executive expertise managing businesses in Canada, Europe, and Asia.
- His experience, coupled with a commitment to a people-first approach, aligns with the culture and values that are integral to Alimentiv.
- I look forward to what we can accomplish together", said Pierre Gaudreault, incoming CEO for Alimentiv.
Retrieved on:
Wednesday, November 8, 2023
Science,
FDA,
Biomarker,
Clinical trial,
Marie Cassidy,
Pathology,
Fibrosis,
Organization,
Phenotype,
Artificial intelligence,
Drug development,
Soft tissue injury,
Disease,
NASH,
Medicine,
Ecosystem,
Partnership,
Personalized medicine,
Digital pathology,
Patient,
Doctor of Philosophy,
Fatty liver disease,
Medical imaging By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
Key Points:
- By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
- AcelaBio, a CAP/CLIA-certified clinical research laboratory known for its end-to-end digital pathology workflows, will carry out tissue sample analysis to generate whole slide images and molecular data.
- Our Fibrosis Digital Pathology biomarker, Ph-FCS, offers exceptional performance as a diagnostic tool for early and severe fibrosis.
- The collaboration between Alimentiv, AcelaBio, and PharmaNest represents a substantial leap forward in integrating precision medicine and digital pathology solutions for MASH clinical trials.
Retrieved on:
Wednesday, November 8, 2023
Science,
FDA,
Biomarker,
Clinical trial,
Marie Cassidy,
Pathology,
Fibrosis,
Organization,
Phenotype,
Artificial intelligence,
Drug development,
Soft tissue injury,
Disease,
NASH,
Medicine,
Ecosystem,
Partnership,
Personalized medicine,
Digital pathology,
Patient,
Doctor of Philosophy,
Fatty liver disease,
Medical imaging By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
Key Points:
- By harnessing the collective expertise of Alimentiv, AcelaBio, and PharmaNest, this collaboration will establish an integrated ecosystem that seamlessly combines high throughput specialty anatomic and molecular pathology, precision medicine technologies, bioinformatics, and AI-powered digital pathology image analysis.
- AcelaBio, a CAP/CLIA-certified clinical research laboratory known for its end-to-end digital pathology workflows, will carry out tissue sample analysis to generate whole slide images and molecular data.
- Our Fibrosis Digital Pathology biomarker, Ph-FCS, offers exceptional performance as a diagnostic tool for early and severe fibrosis.
- The collaboration between Alimentiv, AcelaBio, and PharmaNest represents a substantial leap forward in integrating precision medicine and digital pathology solutions for MASH clinical trials.
Mount Sinai,
Icahn School of Medicine at Mount Sinai,
Contract research organization,
Internal medicine,
MS,
Abstract,
Research,
VARSITY,
The New England Journal of Medicine,
Crohn's and Colitis Canada,
Therapy,
IBD,
Safety,
University,
Inflammatory bowel disease,
Annals of Internal Medicine,
JAMA,
Inflammatory Bowel Diseases,
Publication,
United States Army Medical Research and Development Command,
Dean,
Patient,
Pharmaceutical industry,
MD,
Nature,
Medicine,
Lancet LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
Key Points:
- LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
- The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
- Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
- He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.
Mount Sinai,
Icahn School of Medicine at Mount Sinai,
Contract research organization,
Internal medicine,
MS,
Abstract,
Research,
VARSITY,
The New England Journal of Medicine,
Crohn's and Colitis Canada,
Therapy,
IBD,
Safety,
University,
Inflammatory bowel disease,
Annals of Internal Medicine,
JAMA,
Inflammatory Bowel Diseases,
Publication,
United States Army Medical Research and Development Command,
Dean,
Patient,
Pharmaceutical industry,
MD,
Nature,
Medicine,
Lancet LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
Key Points:
- LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
- The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
- Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
- He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.
Retrieved on:
Tuesday, October 10, 2023
Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
Key Points:
- Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
- Certai was developed using a comprehensive global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the globally leading experts on the assessment and scoring of IBD within clinical trials.
- "Using Certai is like having the world's leading IBD experts on your shoulder," said Dr. Michael Byrne, CEO, Satisfai Health.
- We are very excited to bring these advancements in digital analysis into our portfolio," said Jeff Smith, CEO, Alimentiv.
Retrieved on:
Tuesday, October 10, 2023
Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
Key Points:
- Certai will be exclusively available to Alimentiv's sponsor clients and will provide advanced data insights alongside Alimentiv's central reading services.
- Certai was developed using a comprehensive global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the globally leading experts on the assessment and scoring of IBD within clinical trials.
- "Using Certai is like having the world's leading IBD experts on your shoulder," said Dr. Michael Byrne, CEO, Satisfai Health.
- We are very excited to bring these advancements in digital analysis into our portfolio," said Jeff Smith, CEO, Alimentiv.
